Oenon Holdings (2533) FY2026 Q2 Earnings Report

Quick View

Executive Summary

This earnings result recorded double-digit increases in Operating Income and Ordinary Income, driven by revenue growth and an improvement in the gross profit margin. Revenue was ¥436.7B (+3.3% YoY), Operating Income was ¥25.6B (+10.4%), Ordinary Income was ¥26.5B (+10.5%), and interim Net Income attributable to owners of the parent was ¥19.7B (+6.2%). Profit growth exceeding the revenue growth rate was attributable to high-margin growth in the Enzyme Pharmaceuticals Business, which offset the decline in the profit margin of the core Alcoholic Beverages Business.

Factors Affecting Earnings

【Revenue】Revenue was ¥436.7B, up +3.3% YoY. The core Alcoholic Beverages Business generated ¥400.0B (91.6% of total revenue, +2.4% YoY), the Enzyme Pharmaceuticals Business generated ¥29.7B (+17.8%), and the Real Estate Business generated ¥6.7B (+0.8%). Although the Enzyme Pharmaceuticals Business remains small in terms of revenue, its high growth supported the increase in consolidated revenue.

【Profit and Loss】Operating Income was ¥25.6B (+10.4%), while the gross profit margin improved to 18.7% from 18.3% in the same period of the previous year. Selling, general and administrative expenses increased by +4.1% to ¥56.2B, exceeding the revenue growth rate. By segment, profit in the Alcoholic Beverages Business declined to ¥12.2B (▲9.8% YoY; profit margin of 3.0%), whereas the Enzyme Pharmaceuticals Business recorded a substantial increase in profit to ¥9.4B (+64.8%; profit margin of 31.6%), becoming the primary driver of consolidated profit growth. Extraordinary income of ¥0.9B (including ¥0.7B in gains on sales of fixed assets) supported Net Income, although the divergence from Ordinary Income was limited. In conclusion, the company recorded both revenue and profit growth.

Segment Analysis

The Alcoholic Beverages Business is the core business, accounting for 91.6% of total revenue; however, segment profit declined to ¥12.2B (▲9.8% YoY), and its profit margin decreased to 3.0% from 3.5% in the previous year. The Enzyme Pharmaceuticals Business generated segment profit of ¥9.4B (+64.8% YoY) with a profit margin of 31.6%, making it the most profitable business company-wide and accounting for approximately 36.6% of consolidated Operating Income of ¥25.6B. The Real Estate Business is small in scale, with revenue of ¥6.7B, but is a highly profitable and stable source of earnings, with a profit margin of 59.5%. Overall, the portfolio is characterized by a two-pole structure: dependence on the low-margin Alcoholic Beverages Business and expansion of the high-margin Enzyme Pharmaceuticals and Real Estate Businesses.

Key Financial Indicators

【Profitability】Operating Income Margin improved to 5.9% from 5.5% in the previous year, while Net Income Margin improved to 4.5% from 4.4%. However, the gross profit margin remained at a limited level of 18.7%, reflecting the structure of the Alcoholic Beverages Business, which has a high cost ratio. Annualized ROE was a favorable 14.0%. 【Cash Flow Quality】Operating Cash Flow (OCF) remained at ¥0.3B, and its ratio to interim Net Income of ¥19.8B was an exceptionally low 0.02x, indicating that earnings have not yet been converted into cash. While the ¥18.3B increase in inventories and ¥9.8B decrease in trade payables consumed cash, the ¥50.4B decrease in trade receivables was a source of cash inflow. 【Investment Efficiency】Investing Cash Flow was negative ¥11.1B, as the company continued capital expenditures exceeding depreciation and amortization of ¥10.2B; Free Cash Flow was negative ¥10.7B. 【Financial Soundness】The Equity Ratio improved to 50.6% from a level equivalent to 44.2% in the previous year, and Net Assets accumulated to ¥282.4B. Meanwhile, short-term borrowings increased to ¥44.5B from ¥19.5B in the previous year. The increasing short-term nature of liabilities requires monitoring.

Cash Flow Analysis

Operating Cash Flow remained at ¥0.3B, improving from negative ¥3.8B in the same period of the previous year, but cash conversion of earnings was exceptionally weak relative to interim Net Income of ¥19.8B. The ¥50.4B decrease in trade receivables contributed to cash inflows, while the ¥18.3B increase in inventories, ¥9.8B decrease in trade payables, and ¥6.6B payment of corporate income taxes put pressure on cash flow. Investing Cash Flow was negative ¥11.1B as the company continued investing in property, plant and equipment, resulting in Free Cash Flow of negative ¥10.7B when combined with Operating Cash Flow. Financing Cash Flow was positive ¥10.2B, primarily reflecting a net increase in short-term borrowings of ¥25.0B. This indicates that part of shareholder returns, including ¥3.2B in share repurchases and dividend payments, was financed through borrowings. The normalization of Operating Cash Flow and reduction of dependence on short-term borrowings will be key points in future cash management.

Earnings Quality

The double-digit increases in Operating Income and Ordinary Income were supported by the recurring factor of gross margin improvement, in addition to the structural factor of high-margin growth in the Enzyme Pharmaceuticals Business. Non-operating income and expenses remained within a recurring range, with income of ¥2.1B, including ¥0.6B in dividend income, against expenses of ¥1.1B. Extraordinary income of ¥0.9B (¥0.7B in gains on sales of fixed assets and ¥0.2B in gains on sales of investment securities) was a temporary factor. After offsetting extraordinary losses of ¥0.3B (losses on disposal and sales of fixed assets), the net positive contribution was ¥0.6B. Comprehensive Income was ¥22.1B, exceeding Net Income of ¥19.8B, primarily due to a ¥3.3B increase in valuation difference on securities. On the other hand, the extremely small level of Operating Cash Flow relative to Net Income indicates a substantial accrual—i.e., a divergence between accounting profits and cash. Deterioration in working capital, such as the increase in inventories and decrease in trade payables, weighed on earnings quality.

Earnings Forecast and Guidance

The full-year forecast calls for Revenue of ¥890.0B (+1.6% YoY), Operating Income of ¥39.5B (▲4.5%), and Ordinary Income of ¥40.0B (▲6.8%), implying a full-year decline in profit in contrast to the profit growth trend in the first half. First-half progress rates were 49.1% for Revenue, 64.7% for Operating Income, and 66.3% for Ordinary Income, all exceeding the standard progress rate of 50%. Operating Income of approximately ¥13.9B is required in the second half, representing a plan for a substantial decline from the first-half result of ¥25.6B. Profitability trends in the core Alcoholic Beverages Business will be the key to achieving the second-half plan. There were no revisions to the earnings forecast or dividend forecast during the quarter.

Shareholder Returns

The full-year dividend forecast is ¥12.0 per share, an increase from the previous year's dividend of ¥11. Based on the average number of shares outstanding during the period of 56,208 thousand shares, the annual total dividend is estimated at approximately ¥6.8B, resulting in a Payout Ratio of approximately 23% against the full-year forecast of ¥29.0B in Net Income attributable to owners of the parent. The company conducted share repurchases of ¥3.2B during the first half; therefore, the Total Return Ratio including dividends is higher than the Payout Ratio alone. First-half Free Cash Flow was negative ¥10.7B, and shareholder returns, including dividends and share repurchases, were not funded solely by Operating Cash Flow and involved financing through short-term borrowings. This point should be considered when evaluating the sustainability of shareholder returns.

Risk Factors

1. Declining profitability in the core business: Segment profit in the Alcoholic Beverages Business, which accounts for 91.6% of total revenue, declined ▲9.8% YoY, while its profit margin fell from 3.5% to 3.0%. If increases in raw material, energy, and logistics costs cannot be sufficiently passed on to customers, the impact on the consolidated profit margin could be significant.

2. Low cash generation capacity: Operating Cash Flow was ¥0.3B, representing only 0.02x interim Net Income of ¥19.8B. If the increase in inventories and decrease in trade payables continue, dependence on external financing could become prolonged.

3. Dependence on short-term funding: Short-term borrowings increased 128.2% from ¥19.5B in the previous year to ¥44.5B, with the majority of liabilities concentrated in the short term. The increasing dependence on short-term refinancing while Free Cash Flow remains negative ¥10.7B requires monitoring.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (food_beverage)

Profitability and Returns

As industry median data has not been sufficiently established, comparisons based on absolute levels are limited.

Growth and Capital Efficiency

As industry median data has not been sufficiently established, comparisons based on absolute levels are limited.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Operating Income Margin improved to 5.9% from 5.5% in the previous year, achieving profit growth exceeding the revenue growth rate of 3.3%. The driver was the Enzyme Pharmaceuticals Business, which accounts for 6.8% of total revenue; segment profit increased +64.8% YoY, and its profit margin of 31.6% was substantially above the company-wide average.

2. In contrast to the improvement in profit and loss, cash flow was weak, with Operating Cash Flow of ¥0.3B and Free Cash Flow of negative ¥10.7B, while short-term borrowings increased +128.2% YoY. Monitoring cash flow trends is important when evaluating earnings quality.

3. The full-year Operating Income forecast calls for a decline of ▲4.5% YoY. Although the first-half progress rate is high at 64.7%, the plan assumes a profit level in the second half that is substantially below the first-half result. A recovery in the profitability of the core Alcoholic Beverages Business will be the focus of second-half performance.

Theoretical Share Price (Reference Value)

Sensitivity: ¥513〜¥543 at ±1% for the Cost of Equity, and ¥527〜¥528 at ±0.1 for ω.

Notes:

• Since Net Income progress against the full-year forecast (68%) exceeds the standard level (50%), Forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of plan tend to outperform their forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net Assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because Net Assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

（Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices）

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---